This study looks at the long-term safety of a medicine called lutetium (177Lu) vipivotide tetraxetan in men with prostate cancer. It is designed to learn more about any risks linked to this treatment after patients have received it in earlier studies. Participants will be monitored for up to 10 years after their first dose, focusing on their health and any side effects.
The trial's ID number is NCT05803941. This is a Phase 4 study, which means it is looking at the long-term safety of the treatment. The study is FDA-regulated and aims to include about 700 participants.
Who can join
Men aged 18 to 100 years can join this study. They must have received at least one dose of lutetium in a previous clinical trial for prostate cancer. The study team will check to confirm who is eligible to participate.
Condition
Prostate Cancer
Age group
Adult, Older adult
Sex
Male
The study team makes the final call on eligibility.
What happens in the study
Participants will not receive any new treatment during this study. Instead, they will have check-ups every 6 to 8 months for up to 10 years. They will be monitored for any health changes or side effects after their initial treatment with lutetium.
Where
This trial is enrolling at 24 locations. Recruiting sites are listed first.
Directs translational prostate cancer research, MSK. Treats prostate cancer, bladder cancer, testicular cancer and penile cancer. Also treats kidney cancer.
Leads translational research at Masonic Cancer Center. Treats prostate cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Vice Chair of Urology and Robotic Operations and Director of the Comprehensive Kidney Cancer Program. Treats bladder cancer, penile cancer, prostate cancer and testicular cancer. Also treats kidney cancer.